

PRESS RELEASE

Lund, Sweden, November 7, 2023

Spago Nanomedical publishes prospectus in connection with forthcoming rights issue

The Board of Directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has prepared an EU Growth Prospectus (the "Prospectus") relating to the fully secured rights issue of units of approximately SEK 30.6 million before transaction costs (the "Rights Issue"), which was proposed by the Board of Directors on October 5, 2023, and resolved by the Extraordinary General Meeting held on October 31, 2023. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary of the Rights Issue

- Each existing share in the Company as of the record date on November 7, 2023, entitles the holder to seven (7) unit rights. Five (5) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of one (1) share and one (1) warrant of series TO12.
- The subscription price in the Rights Issue is set at SEK 0.24 per unit, equivalent to SEK 0.24 per new share. The warrants are issued free of charge.
- The subscription period runs from November 9, 2023, up to and including November 23, 2023.
- Prior of the Rights Issue, the Company has received subscription commitments and entered into guarantee commitments totaling approximately SEK 30.6 million, equivalent to 100 percent of the Rights Issue.
- The proceeds from the Rights Issue will enable, among other things, the ongoing development of Tumorad, including the inclusion of patients and the collection of initial results in the first clinical study with Tumorad in cancer patients.

"We see great potential shareholder value in advancing and accelerating the development of Tumorad, given a significant market potential and a great interest in the radionuclide therapy area from both investors and pharmaceutical companies. This capital raise gives us the conditions to focus fully on continuing to build value in Tumorad," says Mats Hansen, CEO of Spago Nanomedical.

Prospectus

The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on November 7, 2023, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's, Hagberg & Aneborn Fondkommission AB's and Redeye AB's respective websites (www.spagonanomedical.se, www.hagberganeborn.se, www.redeye.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the Company's, Hagberg & Aneborn Fondkommission AB's, and Redeye AB's respective websites.

Timetable for the Rights Issue

November 7, 2023	Record date for the Rights Issue
November 9 – 20, 2023	Trading in unit rights
November 9 – 23, 2023	Subscription period
November 9, 2023 – Until the Rights Issue is registered with the Swedish Companies Registration Office	Trading in paid subscribed units (Sw. “BTU”)
Around November 27, 2023	Estimated publication of the outcome in the Rights Issue

Advisors

Redeye AB acts as financial advisor, and Advokatfirman Cederquist KB act as legal advisor to Spago Nanomedical in connection with the Rights Issue.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish company in clinical development phase. The company’s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical’s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company.

IMPORTANT INFORMATION

*This announcement does not constitute and is not a part of an offer to sell securities. Copies of this announcement are not made and may not be distributed, published or sent to the United States, Australia, Hong-Kong, Japan, Canada, Switzerland, Singapore, South Africa or New Zealand or any other jurisdiction where distribution of this press release would be unlawful or require registration or other measures. This announcement is for information purposes only and does not constitute a prospectus or any other offer to sell or a solicitation to offer to acquire any securities in the United States or any other jurisdiction. Securities that may be issued in connection with the transactions referred to in this announcement will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), and consequently will not be offered or sold within the United States.*

*This announcement does not constitute a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and the Council (the “**Prospectus Regulation**”). This press release does not contain and does not constitute an invitation or an offer to acquire, sell, subscribe or otherwise trade in shares, warrants, unit rights or other securities of Spago Nanomedical in the United States or elsewhere. The invitation to affected persons to subscribe for units in Spago Nanomedical will only take place through the prospectus published by Spago Nanomedical which can be found on the Company's website, www.spagonanomedical.se. The prospectus contains, among other things, risk factors, certain financial information and information about the Company's management and Board of Directors. This press release has not been approved by any regulatory authority and does not constitute a prospectus. Investors should not subscribe or acquire securities referred to in this press release except on the basis of the information contained in the published prospectus.*

Topics discussed in this announcement may constitute forward looking statements. Forward looking statements are statements that are not historical facts that can be identified by the use of words such as, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. Forward looking statements in this press release are based on various assumptions, many of which in turn are based on further assumptions. Although Spago Nanomedical believes these assumptions were reasonable when made, these assumptions are inherently associated with known and unknown material risks, uncertainties, unforeseen events and other important factors that are difficult or impossible to predict and that are beyond its control. Such risks, uncertainties, unforeseen events and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward looking statements. Information, opinions and forward looking statements contained in this announcement speak only as at its date, and may be changed without notice.

Spago Nanomedical publishes prospectus in connection with forthcoming rights issue